HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Robert A Hegele Selected Research

mipomersen

12/2015Novel therapeutics in hypertriglyceridemia.
11/2015Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council.
8/2014Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society.
10/2010Mipomersen as a potential adjunctive therapy for hypercholesterolemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Robert A Hegele Research Topics

Disease

63Cardiovascular Diseases (Cardiovascular Disease)
01/2022 - 05/2004
43Hypertriglyceridemia
05/2022 - 01/2002
43Dyslipidemias (Dyslipidemia)
01/2022 - 12/2002
39Hyperlipoproteinemia Type II (Familial Hypercholesterolemia)
04/2022 - 03/2002
39Atherosclerosis
03/2022 - 03/2002
24Type 2 Diabetes Mellitus (MODY)
01/2022 - 01/2002
22Hypertension (High Blood Pressure)
10/2021 - 06/2004
22Insulin Resistance
01/2021 - 02/2002
21Pancreatitis
04/2022 - 01/2006
16Lipodystrophy
01/2022 - 12/2002
15Obesity
01/2022 - 02/2002
14Hypercholesterolemia
01/2022 - 02/2005
14Metabolic Syndrome (Dysmetabolic Syndrome X)
01/2022 - 10/2003
13Coronary Artery Disease (Coronary Atherosclerosis)
01/2019 - 03/2004
12Hyperlipoproteinemia Type I (Lipoprotein Lipase Deficiency, Familial)
04/2022 - 03/2002
12Homozygous Familial Hypercholesterolemia
03/2022 - 02/2005
12Hyperlipidemias (Hyperlipidemia)
01/2021 - 01/2002
12Xanthomatosis (Xanthoma)
01/2018 - 10/2002
12Familial Partial Lipodystrophy (Dunnigan Syndrome)
12/2014 - 03/2002
11Myocardial Infarction
12/2021 - 05/2007
10Muscular Diseases (Myopathy)
01/2018 - 03/2007
9Abetalipoproteinemia (Bassen Kornzweig Syndrome)
03/2022 - 08/2010
9Genetic Risk Score
12/2021 - 01/2013
8Vascular Diseases (Vascular Disease)
04/2022 - 04/2003
8Hypobetalipoproteinemias (Hypobetalipoproteinemia)
03/2022 - 04/2003
8Stroke (Strokes)
01/2022 - 05/2003
8Diabetes Mellitus
01/2022 - 05/2007
8Chronic Renal Insufficiency
01/2021 - 05/2007
7Inborn Genetic Diseases (Disease, Hereditary)
10/2020 - 09/2004
7Coronary Disease (Coronary Heart Disease)
09/2019 - 03/2002
6Neoplasms (Cancer)
12/2018 - 10/2004
5Hyperlipoproteinemias
01/2019 - 09/2007
5Heart Failure
01/2018 - 05/2007
5Cerebrovascular Disorders (Cerebrovascular Occlusion)
01/2018 - 05/2007
5Isolated Systolic Hypertension
01/2017 - 05/2007
4Myalgia
02/2021 - 06/2009
4Cognitive Dysfunction
01/2021 - 01/2016
4Inflammation (Inflammations)
01/2021 - 08/2009
4Progeria (Hutchinson Gilford Syndrome)
10/2020 - 10/2003
4Hypoalphalipoproteinemias (Hypoalphalipoproteinemia)
01/2019 - 07/2002
4Neurodegenerative Diseases (Neurodegenerative Disease)
01/2019 - 08/2013
4Rhabdomyolysis
01/2016 - 03/2007
4Atherosclerotic Plaque (Atheroma)
03/2013 - 02/2004

Drug/Important Bio-Agent (IBA)

68LDL CholesterolIBA
04/2022 - 03/2002
58Triglycerides (Triacylglycerol)IBA
05/2022 - 01/2002
55LipidsIBA
04/2022 - 08/2003
35Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
03/2022 - 03/2007
34CholesterolIBA
11/2021 - 02/2005
34HDL CholesterolIBA
10/2021 - 07/2002
32oxidized low density lipoproteinIBA
04/2022 - 02/2004
29DNA (Deoxyribonucleic Acid)IBA
01/2022 - 01/2002
26Lipoproteins (Lipoprotein)IBA
03/2022 - 01/2002
24ApolipoproteinsIBA
03/2022 - 07/2002
21LDL Lipoproteins (beta Lipoproteins)IBA
01/2022 - 02/2004
18Proteins (Proteins, Gene)FDA Link
01/2021 - 07/2002
16Lamin Type A (Lamin A)IBA
10/2020 - 12/2002
14Apolipoproteins B (ApoB)IBA
03/2022 - 04/2003
13Ezetimibe (Zetia)FDA Link
04/2022 - 10/2005
13LDL Receptors (LDL Receptor)IBA
01/2022 - 02/2005
12Insulin (Novolin)FDA Link
12/2021 - 04/2002
11Pharmaceutical PreparationsIBA
03/2022 - 06/2007
11Apolipoproteins E (ApoE)IBA
01/2021 - 02/2008
10Apolipoprotein C-II (ApoC2)IBA
01/2020 - 06/2011
10Glucose (Dextrose)FDA LinkGeneric
01/2018 - 04/2002
9microsomal triglyceride transfer proteinIBA
03/2022 - 08/2010
9BMS201038IBA
01/2022 - 01/2013
9Biomarkers (Surrogate Marker)IBA
01/2021 - 05/2004
9PPAR gammaIBA
10/2009 - 12/2002
8Lipoprotein(a)IBA
01/2022 - 10/2008
7Lipoprotein Lipase (Diacylglycerol Lipase)IBA
07/2018 - 03/2002
7Apolipoprotein A-I (Apolipoprotein A1)IBA
03/2013 - 07/2002
6Apolipoprotein C-IIIIBA
04/2022 - 01/2016
6Proprotein Convertase 9IBA
01/2022 - 12/2013
6PCSK9 InhibitorsIBA
01/2022 - 01/2018
6Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
01/2018 - 05/2007
6Angiotensin Receptor AntagonistsIBA
01/2018 - 05/2007
6EnzymesIBA
10/2015 - 12/2005
5ChylomicronsIBA
04/2022 - 03/2002
5VitaminsIBA
03/2022 - 10/2004
5O(4)-methylthymidine triphosphateIBA
03/2022 - 07/2016
5SubtilisinIBA
03/2021 - 11/2013
5Proprotein Convertases (Pro-Opiomelanocortin Converting Enzyme)IBA
03/2021 - 11/2013
5HDL LipoproteinsIBA
10/2020 - 07/2002
5Biological ProductsIBA
07/2020 - 06/2004
5Lipase (Acid Lipase)FDA Link
01/2020 - 03/2002
5Cholesterol Ester Transfer ProteinsIBA
01/2018 - 02/2008
5Calcium Channel Blockers (Blockers, Calcium Channel)IBA
01/2016 - 05/2007
51,4-dihydropyridine (dihydropyridine)IBA
07/2011 - 05/2007
4evolocumabIBA
04/2022 - 05/2019
4ISIS 304801IBA
04/2022 - 12/2015
4Antihypertensive Agents (Antihypertensives)IBA
01/2022 - 01/2003
4Fibric Acids (Fibrates)IBA
02/2020 - 10/2007
4LeptinIBA
01/2018 - 01/2003
4mipomersenIBA
12/2015 - 10/2010
4AdiponectinIBA
01/2013 - 01/2003
4Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA
07/2011 - 05/2007
4ThiazidesIBA
05/2010 - 05/2007
4DiureticsIBA
05/2010 - 05/2007

Therapy/Procedure

54Therapeutics
04/2022 - 02/2004
4Plasma Exchange
01/2022 - 08/2012